[
  {
    "ts": null,
    "headline": "Stock Market Today: Dow Rises, Powell Sees No 'Risk-Free Path' After Rate Cut; Palantir Jumps (Live Coverage)",
    "summary": "Stock Market Today: The Dow Jones index rises Wednesday after the Fed rate cut. Microsoft stock sold off.",
    "url": "https://finnhub.io/api/news?id=0f97b1a56d8f8edb0f1a05ae0c5fc71f4373a24b1488febd7574da9c6630eaa0",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1765396355,
      "headline": "Stock Market Today: Dow Rises, Powell Sees No 'Risk-Free Path' After Rate Cut; Palantir Jumps (Live Coverage)",
      "id": 137749633,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "Stock Market Today: The Dow Jones index rises Wednesday after the Fed rate cut. Microsoft stock sold off.",
      "url": "https://finnhub.io/api/news?id=0f97b1a56d8f8edb0f1a05ae0c5fc71f4373a24b1488febd7574da9c6630eaa0"
    }
  },
  {
    "ts": null,
    "headline": "Johnson & Johnson (JNJ) Announces Updated Results From the Phase 3 CARTITUDE-4 Study",
    "summary": "Johnson & Johnson (NYSE:JNJ) is one of the best pharma stocks to invest in. Johnson & Johnson (NYSE:JNJ) announced on December 6 the updated results from the Phase 3 CARTITUDE-4 study that supported durable treatment-free remissions as early as second line treatment with CARVYKTI, reporting that the disease did not progress and no further treatment was […]",
    "url": "https://finnhub.io/api/news?id=8f1282606cf4093049168fa7d908beaa40136e9dad20cf5b243be858ad913747",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1765384120,
      "headline": "Johnson & Johnson (JNJ) Announces Updated Results From the Phase 3 CARTITUDE-4 Study",
      "id": 137749865,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "Johnson & Johnson (NYSE:JNJ) is one of the best pharma stocks to invest in. Johnson & Johnson (NYSE:JNJ) announced on December 6 the updated results from the Phase 3 CARTITUDE-4 study that supported durable treatment-free remissions as early as second line treatment with CARVYKTI, reporting that the disease did not progress and no further treatment was […]",
      "url": "https://finnhub.io/api/news?id=8f1282606cf4093049168fa7d908beaa40136e9dad20cf5b243be858ad913747"
    }
  },
  {
    "ts": null,
    "headline": "JNJ vs. PFE: Which Blue-Chip Drug Stock is the Better Investment Now?",
    "summary": "JNJ and PFE battle patent cliffs and policy headwinds, but rising estimates and stronger 2025 momentum push JNJ ahead in this blue-chip faceoff.",
    "url": "https://finnhub.io/api/news?id=1381ba816a9fbdf0f7caa089d7eb1c2f8328135096e66fb763969c39e53e70fd",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1765369860,
      "headline": "JNJ vs. PFE: Which Blue-Chip Drug Stock is the Better Investment Now?",
      "id": 137749866,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "JNJ and PFE battle patent cliffs and policy headwinds, but rising estimates and stronger 2025 momentum push JNJ ahead in this blue-chip faceoff.",
      "url": "https://finnhub.io/api/news?id=1381ba816a9fbdf0f7caa089d7eb1c2f8328135096e66fb763969c39e53e70fd"
    }
  },
  {
    "ts": null,
    "headline": "AstraZeneca: A Rare Compound Growth Opportunity In Biopharma",
    "summary": "AstraZeneca PLC is rated a Buy due to strong growth, prudent R&D reinvestment, low leverage and resilience. Learn more about AZN stock here.",
    "url": "https://finnhub.io/api/news?id=7607e031783e690b2011e6797309b77b7a7084aa1403fc9ee0fe0c21f814be29",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1765362409,
      "headline": "AstraZeneca: A Rare Compound Growth Opportunity In Biopharma",
      "id": 137747724,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1307043297/image_1307043297.jpg?io=getty-c-w1536",
      "related": "JNJ",
      "source": "SeekingAlpha",
      "summary": "AstraZeneca PLC is rated a Buy due to strong growth, prudent R&D reinvestment, low leverage and resilience. Learn more about AZN stock here.",
      "url": "https://finnhub.io/api/news?id=7607e031783e690b2011e6797309b77b7a7084aa1403fc9ee0fe0c21f814be29"
    }
  },
  {
    "ts": null,
    "headline": "Skip The Market Darling Eli Lilly; Buy The Underdog Novo Nordisk",
    "summary": "Explore undervalued Novo Nordisk (NVO) vs. Eli Lilly, key growth insights, and investment risks.",
    "url": "https://finnhub.io/api/news?id=614c134a33e647cb51682ced84828d369bf8c32664de7c0902784ed0e04eab7b",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1765359546,
      "headline": "Skip The Market Darling Eli Lilly; Buy The Underdog Novo Nordisk",
      "id": 137747549,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/182825316/image_182825316.jpg?io=getty-c-w1536",
      "related": "JNJ",
      "source": "SeekingAlpha",
      "summary": "Explore undervalued Novo Nordisk (NVO) vs. Eli Lilly, key growth insights, and investment risks.",
      "url": "https://finnhub.io/api/news?id=614c134a33e647cb51682ced84828d369bf8c32664de7c0902784ed0e04eab7b"
    }
  },
  {
    "ts": null,
    "headline": "Johnson & Johnson (JNJ): Revisiting Valuation After a Strong Multi‑Month Share Price Rally",
    "summary": "Johnson & Johnson (JNJ) has quietly ground higher, with the stock up roughly 7% over the past month and nearly 14% in the past 3 months, drawing fresh attention from income focused investors. See our latest analysis for Johnson & Johnson. Zooming out, that steady climb sits on top of a powerful backdrop, with a roughly 39% year to date share price return and a three year total shareholder return above 22% suggesting momentum is still firmly building as investors reassess Johnson & Johnson’s...",
    "url": "https://finnhub.io/api/news?id=4a7d95f64300178c513dcf17d6b9f95faa1bf0c9a132a3d6f5f5b99bc0de0163",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1765325487,
      "headline": "Johnson & Johnson (JNJ): Revisiting Valuation After a Strong Multi‑Month Share Price Rally",
      "id": 137749867,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "Johnson & Johnson (JNJ) has quietly ground higher, with the stock up roughly 7% over the past month and nearly 14% in the past 3 months, drawing fresh attention from income focused investors. See our latest analysis for Johnson & Johnson. Zooming out, that steady climb sits on top of a powerful backdrop, with a roughly 39% year to date share price return and a three year total shareholder return above 22% suggesting momentum is still firmly building as investors reassess Johnson & Johnson’s...",
      "url": "https://finnhub.io/api/news?id=4a7d95f64300178c513dcf17d6b9f95faa1bf0c9a132a3d6f5f5b99bc0de0163"
    }
  }
]